Compare RITM & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RITM | APGE |
|---|---|---|
| Founded | 2011 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 4.7B |
| IPO Year | 2012 | 2023 |
| Metric | RITM | APGE |
|---|---|---|
| Price | $5.08 | $134.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | $14.06 | ★ $109.67 |
| AVG Volume (30 Days) | ★ 5.5M | 1.2M |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | ★ 10.35% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $4,590,228,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $28.68 | N/A |
| P/E Ratio | $64.88 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.43 | $35.39 |
| 52 Week High | $12.74 | $134.88 |
| Indicator | RITM | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 58.62 | 77.42 |
| Support Level | $8.98 | $134.03 |
| Resistance Level | $10.27 | $134.88 |
| Average True Range (ATR) | 0.20 | 0.20 |
| MACD | -0.00 | -0.75 |
| Stochastic Oscillator | 53.96 | 87.65 |
Rithm Capital Corp operates as a real estate investment trust that provides capital and services to the real estate and financial services industries. The company aims to generate attractive risk-adjusted returns in all interest-rate environments through a complementary portfolio of investments and operating businesses. Its investment portfolio is composed of mortgage servicing-related assets (full and excess MSRs and servicer advances), residential securities (and associated call rights), loans (including single-family rental), and consumer loans. Its operating segments are Origination and Servicing; Investment Portfolio; Residential Transitional Lending; and Asset Management.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.